Verastem Inc (NASDAQ:VSTM)’s share price traded down 7.1% during mid-day trading on Tuesday . The company traded as low as $4.83 and last traded at $4.84. 2,537,389 shares traded hands during trading, an increase of 23% from the average session volume of 2,057,513 shares. The stock had previously closed at $5.21.

A number of equities analysts have recently issued reports on the stock. BidaskClub raised shares of Verastem from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 28th. HC Wainwright increased their price objective on shares of Verastem to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, September 25th. Raymond James increased their price objective on shares of Verastem from $7.00 to $12.00 in a research report on Friday, August 10th. Cann reissued a “buy” rating and set a $16.00 price objective on shares of Verastem in a research report on Thursday, August 9th. Finally, BTIG Research set a $17.00 price objective on shares of Verastem and gave the stock a “buy” rating in a research report on Tuesday, September 25th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $14.60.

The stock has a market capitalization of $376.34 million, a PE ratio of -2.75 and a beta of 3.14. The company has a current ratio of 2.97, a quick ratio of 2.97 and a debt-to-equity ratio of 0.20.

Verastem (NASDAQ:VSTM) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.14. The business had revenue of $15.51 million during the quarter. On average, equities analysts anticipate that Verastem Inc will post -1.42 earnings per share for the current year.

In other Verastem news, Director Michael Kauffman purchased 4,000 shares of the company’s stock in a transaction that occurred on Friday, September 28th. The shares were acquired at an average price of $7.49 per share, with a total value of $29,960.00. Following the transaction, the director now owns 4,000 shares in the company, valued at $29,960. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert Forrester purchased 10,500 shares of the company’s stock in a transaction that occurred on Thursday, September 27th. The stock was acquired at an average cost of $7.00 per share, for a total transaction of $73,500.00. Following the transaction, the chief executive officer now owns 209,234 shares in the company, valued at approximately $1,464,638. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 19,500 shares of company stock worth $139,420. 5.50% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in VSTM. State Board of Administration of Florida Retirement System bought a new position in shares of Verastem during the 2nd quarter worth approximately $100,000. HRT Financial LLC bought a new position in shares of Verastem during the 3rd quarter worth approximately $109,000. Pacer Advisors Inc. bought a new position in shares of Verastem during the 3rd quarter worth approximately $123,000. B. Riley Wealth Management Inc. bought a new position in shares of Verastem during the 3rd quarter worth approximately $127,000. Finally, Metropolitan Life Insurance Co. NY bought a new position in shares of Verastem during the 2nd quarter worth approximately $130,000. 48.83% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/verastem-vstm-shares-down-7-1/2662985.html.

About Verastem (NASDAQ:VSTM)

Verastem, Inc, operating as a Verastem Oncology, is a biopharmaceutical company focuses on developing and commercializing medicines to improve the survival of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and is approved dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

Featured Article: Yield Curve

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.